tbuckley/cabot-search huggingface dataset:
Factors Associated With Complete Remission After Rituximab Therapy for Pemphigus
Authors: Carolyn J. Kushner, Shiyu Wang, Napatra Tovanabutra, Donald E. Tsai, Victoria P. Werth, Aimee S. Payne
Journal: JAMA Dermatology (2019)

Rituximab has emerged as a front-line therapy for pemphigus, but prognostic factors for achieving complete remission off therapy (CROT) with oral systemic agents remain unknown.To describe rates of CROT and relapse and identify prognostic factors for achieving CROT after rituximab therapy for pemphigus.A single-center, retrospective, cohort study was conducted at the University of Pennsylvania including 112 patients with pemphigus treated with rituximab with at least 12 months' clinical follow-up after the start of rituximab therapy. Multivariate regression analysis of factors predictive of CROT and Kaplan-Meier analysis of disease relapse were conducted. The study included patients treated with rituximab from March 15, 2005, until December 19, 2016. Data analysis was performed from December 2017 to June 2018.The primary study outcome was CROT after 1 cycle. Secondary study outcomes included rate of CROT or the composite end point of CROT or complete remission on minimal therapy after 1 or more cycle, and median time to relapse. Multivariate regression analysis for prognostic variables for CROT, including age, sex, pemphigus subtype, body mass index (BMI) (calculated as weight in kilograms divided by height in meters squared), disease duration, and dosing regimen, was performed.A total of 112 patients with pemphigus with median 37.8 months (range, 12.1-130.7) follow-up after rituximab therapy were identified. Of these, 65 were women (58.0%). At the time of first rituximab infusion, median age was 52.3 years (range, 20.0-89.3). Including patients who received multiple cycles of rituximab, 79 patients (70.5%) achieved CROT after a median time of 10.5 months (range, 2.0-49.8), and 36 of 72 patients (50.0%) subsequently experienced relapse after a median of 23.3 months (interquartile range, 10.8-50.4 months). Considering only the first cycle of rituximab, 54 patients (48.2%) achieved CROT. Controlling for age, sex, pemphigus subtype, BMI, and disease duration, patients who received lymphoma vs rheumatoid arthritis dosing were 2.70-fold more likely to achieve CROT (odds ratio [OR], 2.70; 95% CI, 1.03-7.12; P = .04). Increasing age was associated with significant increases in achieving CROT (Wald test for trend, P = .01), whereas BMI greater than or equal to 35 was associated with a 0.14 OR (95% CI, 0.03-0.63; P = .01) for achieving CROT, regardless of the dosing regimen. In multivariate analysis, there was no significant difference in CROT rates with sex (OR, 1.01; 95% CI, 0.42-2.50; P = .97), pemphigus subtype (OR, 0.37; 95% CI, 0.09-1.51; P = .17), or disease duration (OR, 0.99; 95% CI, 0.98-1.00; P = .09).Lymphoma dosing and older age may be associated with CROT and BMI greater than or equal to 35 may be a negative prognostic factor for CROT after rituximab therapy for pemphigus. These findings help inform clinical expectations and merit evaluation in future prospective clinical trials.
Effect of Cryotherapy vs Loop Electrosurgical Excision Procedure on Cervical Disease Recurrence Among Women With HIV and High-Grade Cervical Lesions in Kenya
Authors: Sharon A. Greene, Hugo De Vuyst, Grace C. John-Stewart, Barbra A. Richardson, Christine J. McGrath, Kara G. Marson, T. Tony Trinh, Nelly Yatich, Catherine Kiptinness, Anthony Cagle, Evans Nyongesa-Malava, Samah R. Sakr, Nelly R. Mugo, Michael H. Chung
Journal: JAMA (2019)

<h3>Importance</h3> The World Health Organization recommends cryotherapy or loop electrosurgical excision procedure (LEEP) for histologically confirmed cervical intraepithelial neoplasia (CIN) grade 2 or higher regardless of HIV status. Cryotherapy is more feasible in resource-limited settings but may be less effective for women living with HIV. <h3>Objective</h3> To evaluate whether cryotherapy or LEEP is a more effective treatment for high-grade cervical lesions among women with HIV. <h3>Design, Setting, and Participants</h3> Single-center randomized trial conducted among women with HIV and CIN grade 2 or 3. From June 2011 to September 2016, women with HIV in Kenya underwent cervical screening with Papanicolaou testing and confirmatory biopsy. The final date on which a study procedure was administered was September 7, 2016. <h3>Interventions</h3> Women with HIV infection and CIN grade 2 or 3 were randomized 1:1 to receive cryotherapy (n = 200) or LEEP (n = 200) and were followed up every 6 months for 24 months with a Papanicolaou test and confirmatory biopsy. <h3>Main Outcome and Measures</h3> The primary outcome was disease recurrence, defined as CIN grade 2 or higher on cervical biopsy, during the 24-month follow-up period. <h3>Results</h3> Among 400 women who were randomized (median age, 37.4 [interquartile range, 31.9-43.8] years), 339 (85%) completed the trial. Over 2 years, 60 women (30%) randomized to cryotherapy had recurrent CIN grade 2 or higher vs 37 (19%) in the LEEP group (relative risk, 1.71 [95% CI, 1.12-2.65]; risk difference, 7.9% [95% CI, 1.9%-14.0%];<i>P</i> = .01). Adverse events occurred in 40 women (45 events, including change in pathology and death due to other causes) in the cryotherapy group and in 30 women (38 events, including change in pathology and unrelated gynecological complications) in the LEEP group. <h3>Conclusions and Relevance</h3> In this single-center study of women with HIV infection and CIN grade 2 or 3, treatment with LEEP compared with cryotherapy resulted in a significantly lower rate of cervical neoplasia recurrence over 24 months. Cost-effectiveness analysis is necessary to determine whether the additional benefit of LEEP represents an efficient use of the additional resources that would be required. <h3>Trial Registration</h3> ClinicalTrials.gov Identifier:NCT01298596
Oral ferroportin inhibitor ameliorates ineffective erythropoiesis in a model of β-thalassemia
Authors: Vania Manolova, Naja Nyffenegger, Anna Flace, Patrick Altermatt, Ahmet Varol, Cédric Doucerain, Hanna Sundstrom, Franz Dürrenberger
Journal: Journal of Clinical Investigation (2019)

β-Thalassemia is a genetic anemia caused by partial or complete loss of β-globin synthesis, leading to ineffective erythropoiesis and RBCs with a short life span. Currently, there is no efficacious oral medication modifying anemia for patients with β-thalassemia. The inappropriately low levels of the iron regulatory hormone hepcidin enable excessive iron absorption by ferroportin, the unique cellular iron exporter in mammals, leading to organ iron overload and associated morbidities. Correction of unbalanced iron absorption and recycling by induction of hepcidin synthesis or treatment with hepcidin mimetics ameliorates β-thalassemia. However, hepcidin modulation or replacement strategies currently in clinical development all require parenteral drug administration. We identified oral ferroportin inhibitors by screening a library of small molecular weight compounds for modulators of ferroportin internalization. Restricting iron availability by VIT-2763, the first clinical stage oral ferroportin inhibitor, ameliorated anemia and the dysregulated iron homeostasis in the Hbbth3/+ mouse model of β-thalassemia intermedia. VIT-2763 not only improved erythropoiesis but also corrected the proportions of myeloid precursors in spleens of Hbbth3/+ mice. VIT-2763 is currently being developed as an oral drug targeting ferroportin for the treatment of β-thalassemia.
MA22.02 The Impact of Patient Engagement on Study Design and Patient Recruitment in a Pragmatic Trial to Improve Cancer Care Delivery
Authors: A. Bell-Brown, S. Sullivan, G. Lyman, D. Hershman, K. Watabayashi, K. Kreizenbeck, S. Shirley, A. Ciccarella, G. Walia, J. Johnson, C. Seigel, G. Mason, F. Kurttila, B. Segarra-Vazquez, S. Ramsey, B. Haddock Lobo Goulart
Journal: Journal of Thoracic Oncology (2019)
P1.14-05 TP53 Exon 8 Mutation and Prognosis in EGFR-Mutated NSCLC Patients Treated with First-And-Second-Generation TKIs
Authors: M. Canale, E. Petracci, L. Crino, N. De Luigi, V. Ludovini, A. Dubini, S. Baglivo, E. Minenza, E. Chiadini, L. Landi, M. Papi, A. Delmonte, G. Bronte, P. Ulivi
Journal: Journal of Thoracic Oncology (2019)
P1.01-54 Somatic Genome Alterations in Lung Cancer Patients Diagnosed with Li Fraumeni Syndrome
Authors: M. Jove, T. Moran, A. Teule, M. Menendez, M. Gausachs, N. Vilariño, R. Palmero Sánchez, B. Cirauqui, A. Estival, E. Carcereny, M. Domenech, M. Navarro, J. Bosch-Barrera, C. Fina, A. Izquierdo, J.C. Ruffinelli, M. Varela, C. Mesia, A. Hernandez, S. Gonzalez, C. Lazaro, J. Brunet, E. Nadal
Journal: Journal of Thoracic Oncology (2019)
P1.01-105 US Real-World Management of EGFR-Mutated Advanced NSCLC: Prescribing and Attrition Data from First-To-Second-Line Treatment
Authors: K. Reckamp, J. Nieva, A. Taylor, B. Thakrar, J. Wong, D. Potter, N. Bakker, W. Rubinstein, P. Sun
Journal: Journal of Thoracic Oncology (2019)
P1.14-23 Resistance Mechanisms to Osimertinib Treatment in EGFR-Mutated Lung Cancer in a Real Life Cohort
Authors: C. Steendam, P. Atmodimedjo, M. Paats, C. Van Der Leest, J. Von Der Thüsen, W. Dinjens, R. Van Schaik, H. Dubbink, J. Aerts
Journal: Journal of Thoracic Oncology (2019)
P2.01-86 Highly Immunogenic Neoantigens Enhance Tumor Response to Immune Checkpoint Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)
Authors: D. Wu, J. Yang, Y. Liu, X. Hong, K. Zhang, F. Gu, Y. Liu, Z. Zhao, Y. Hu, L. Liu
Journal: Journal of Thoracic Oncology (2019)
P2.13-06 Finding a Place for Pathological Near Complete Response Patients Following Neoadjuvant/Induction Therapy in the TNM Staging
Authors: H. Melek, G. Çetinkaya, T. Sevinç, A. Deligönül, E. Özer, E. Çubukçu, A. Bayram, T. Evrensel, C. Gebitekin
Journal: Journal of Thoracic Oncology (2019)
EP1.11-15 Lung Cancer Screening Program with Low-Dose CT in Greek Population
Authors: K. Domvri, T. Kontakiotis, G. Lazaridis, D. Spyratos, E. Eleftheriadou, K. Porpodis, K. Tsiakitzis, S. Lampaki
Journal: Journal of Thoracic Oncology (2019)
Distinct interaction profiles of the second generation Bcr-Abl inhibitors nilotinib and bosutinib with the ABCG2 multidrug transporter
Authors: Csilla Hegedus, Agota Apati, Katalin Nemet, Csilla Ozvegy-Laczka, Balazs Sarkadi
Journal: Cancer Research (2008)

LB-185  The human ABCG2 transporter provides tissue protection against numerous toxic compounds and accounts for a multidrug-resistant phenotype in cancer cells. It has been documented that ABCG2 displays a high affinity interaction with several small molecule tyrosine kinase inhibitors, including Imatinib (Glivec) that inhibits the Bcr-Abl fusion protein, the molecular marker of chronic myeloid leukemia (CML). In this study we investigated the interaction of ABCG2 with two second generation Bcr-Abl inhibitors already in clinical trials, Nilotinib and Bosutinib. We found that Nilotinib greatly stimulated the ATPase activity of the human wild-type ABCG2 (expressed in cholesterol-loaded Sf9 membranes), reaching a maximum stimulation at a Nilotinib concentration of 10 nM. This compound, in a similar concentration range (10-100 nM), also effectively inhibited Hoechst 33342 dye extrusion in Bcr-Abl+ K562 cells, overexpressing the ABCG2 protein (K562/ABCG2). These data suggest that ABCG2 interacts with Nilotinib with a high affinity, and this agent is a transported substrate for this multidrug transporter. In contrast, Bosutinib showed no stimulatory or inhibitory effect on the ABCG2-ATPase activity up to 1-2 uM concentrations, and in similar concentrations this compound did not inhibit the Hoechst 33342 dye extrusion in K562/ABCG2 cells either. The cytotoxic effects of Nilotinib and Bosutinib, as well as their modulatory potential on ABCG2 function were tested in K562 parental and K562/ABCG2 cells. In the parental K562 cells both of these compounds were cytotoxic at very low concentrations, the IC50 values being lower than 5 nM for Nilotinib, and about 10 nM for Bosutinib. In the K562/ABCG2 cells the IC50 vaules for Nilotinib increased by about one order of magnitude, up to 50 nM, while ABCG2 overexpression had no measurable effect on the cytotoxicity of Bosutinib. Based on these data we suggest that the novel Bcr-Abl inhibitors have major differences in their interaction profiles with ABCG2. While Nilotinib is a high affinity substrate and at higher concentrations is an effective inhibitor of the transporter, Bosutinib does not significantly interact with ABCG2 at therapeutically relevant concentrations. These findings may provide important information regarding the anticancer effects and ADME-Tox properties of these novel agents.
P1.03-26 Genetic and Molecular Profiling of Non-Smoking Related Lung Adenocarcinomas
Authors: E. Pros, M. Saigi, J.J. Alburquerque Béjar, M.J. Pajares, B. Martinez-Delgado, J. Carretero, R. Tonda, A. Esteve-Codina, S. Verdura, I. Català, N. Reguart, O. Juan, E. Nadal, E. Felip, L. Montuenga, M. Sanchez-Cespedes
Journal: Journal of Thoracic Oncology (2019)
EP1.12-36 Treatment Outcomes and Risk Factors of Limited-Stage Small Cell Lung Cancer Patients Treated with Chemoradiotherapy
Authors: T. Hayakawa, I. Soda, A. Sekiguchi, S. Kawakami, M. Kubota, H. Mitsufuji, S. Igawa, T. Fukui, K. Naoki, K. Hayakawa, H. Ishiyama
Journal: Journal of Thoracic Oncology (2019)
Drug policy: MPs call for radical change to stem rising death rate
Authors: Elisabeth Mahase
Journal: BMJ (2019)

The scale of drug related deaths in the UK is now a “public health emergency” and can be tackled only with a “radical change” in policy, a cross party panel of MPs has said.1

The members of the House of Commons Health and Social Care Committee called for a health approach rather than a criminal justice approach to drug use and recommended moving responsibility for drug policy from the Home Office to the Department of Health and Social Care.

In its report on drug policy the committee said that the government should consult on downgrading drug possession for personal use from a criminal offence to a civil matter, should conduct pilot studies of drug consumption rooms in areas of high use, and should provide greater support to people at …
Transmissibility and potential for disease progression of drug resistant<i>Mycobacterium tuberculosis</i>: prospective cohort study
Authors: Mercedes C Becerra, Chuan-Chin Huang, Leonid Lecca, Jaime Bayona, Carmen Contreras, Roger Calderon, Rosa Yataco, Jerome Galea, Zibiao Zhang, Sidney Atwood, Ted Cohen, Carole D Mitnick, Paul Farmer, Megan Murray
Journal: BMJ (2019)

To measure the association between phenotypic drug resistance and the risk of tuberculosis infection and disease among household contacts of patients with pulmonary tuberculosis.106 district health centers in Lima, Peru between September 2009 and September 2012.Prospective cohort study.10 160 household contacts of 3339 index patients with tuberculosis were classified on the basis of the drug resistance profile of the patient: 6189 were exposed to drug susceptible strains of Mycobacterium tuberculosis, 1659 to strains resistant to isoniazid or rifampicin, and 1541 to strains that were multidrug resistant (resistant to isoniazid and rifampicin).Tuberculosis infection (positive tuberculin skin test) and the incidence of active disease (diagnosed by positive sputum smear or chest radiograph) after 12 months of follow-up.Household contacts exposed to patients with multidrug resistant tuberculosis had an 8% (95% confidence interval 4% to 13%) higher risk of infection by the end of follow-up compared with household contacts of patients with drug sensitive tuberculosis. The relative hazard of incident tuberculosis disease did not differ among household contacts exposed to multidrug resistant tuberculosis and those exposed to drug sensitive tuberculosis (adjusted hazard ratio 1.28, 95% confidence interval 0.9 to 1.83).Household contacts of patients with multidrug resistant tuberculosis were at higher risk of tuberculosis infection than contacts exposed to drug sensitive tuberculosis. The risk of developing tuberculosis disease did not differ among contacts in both groups. The evidence invites guideline producers to take action by targeting drug resistant and drug sensitive tuberculosis, such as early detection and effective treatment of infection and disease.ClinicalTrials.gov NCT00676754.
Comparison of real costs in the French healthcare system in newly diagnosed patients with pemphigus for first‐line treatment with rituximab vs. standard corticosteroid regimen: data from a national multicentre trial
Authors: V. Hébert, T. Vermeulin, L. Tanguy, B. Tedbirt, C. Mignard, J. Bénichou, P. Joly
Journal: British Journal of Dermatology (2019)

Rituximab has been demonstrated to be highly effective as a first‐line treatment for moderate‐to‐severe pemphigus; however, its high cost can be considered a limitation of this treatment. To compare direct costs of two regimens, rituximab + short‐term prednisone vs. prednisone alone, tested in the Ritux3 trial. Patients were randomly assigned to receive 2 g of rituximab and two 500‐mg maintenance infusions at month 12 and month 18 along with low doses of prednisone for 3–6 months, or high doses of prednisone alone tapered over 12–18 months. We estimated the direct costs related to (i) protocol (treatments, consultations, hospitalizations); (ii) unfavourable disease course (relapse); and (iii) adverse events in both treatment groups during a 3‐year follow‐up. Annual individual cost discrepancies related to drugs decreased from +€3597 to −€1589 from the first to the third year, which corresponded to an initially higher cost in the rituximab group, counterbalanced during follow‐up by costs related to treatment of patients with persistent disease activity/relapses in the standard corticosteroid (CS) group. Individual costs relating to treatment of adverse events were higher in the standard CS group (€4352) than in the rituximab group (€2468). Overall, mean individual total cost over the 3 years of follow‐up was €13 997 in the standard CS arm vs. €14 818 in the rituximab arm, corresponding to a difference of €821 more per patient (+6%). First‐line treatment of pemphigus with rituximab results in a slightly greater cost compared with a standard CS regimen. What's already known about this topic Rituximab is the most effective treatment for moderate‐to‐severe pemphigus. Rituximab cost might be considered as a limitation of this treatment. What does this study add? After 3 years of follow‐up, mean individual total cost for a patient with first‐line treatment with rituximab was €14 818 vs. €13 997 with standard corticosteroids (CS), resulting in a slightly higher cost of €821 (+6%). The initially greater cost of rituximab was counterbalanced by costs related to management of flares/relapses in patients treated with a standard CS regimen.
Fracture repair requires TrkA signaling by skeletal sensory nerves
Authors: Zhu Li, Carolyn A. Meyers, Leslie Chang, Seungyong Lee, Zhi Li, Ryan Tomlinson, Ahmet Hoke, Thomas L. Clemens, Aaron W. James
Journal: Journal of Clinical Investigation (2019)

Bone is richly innervated by nerve growth factor–responsive (NGF-responsive) tropomyosin receptor kinase A–expressing (TrKa-expressing) sensory nerve fibers, which are required for osteochondral progenitor expansion during mammalian skeletal development. Aside from pain sensation, little is known regarding the role of sensory innervation in bone repair. Here, we characterized the reinnervation of tissue following experimental ulnar stress fracture and assessed the impact of loss of TrkA signaling in this process. Sequential histological data obtained in reporter mice subjected to fracture demonstrated a marked upregulation of NGF expression in periosteal stromal progenitors and fracture-associated macrophages. Sprouting and arborization of CGRP+TrkA+ sensory nerve fibers within the reactive periosteum in NGF-enriched cellular domains were evident at time points preceding periosteal vascularization, ossification, and mineralization. Temporal inhibition of TrkA catalytic activity by administration of 1NMPP1 to TrkAF592A mice significantly reduced the numbers of sensory fibers, blunted revascularization, and delayed ossification of the fracture callus. We observed similar deficiencies in nerve regrowth and fracture healing in a mouse model of peripheral neuropathy induced by paclitaxel treatment. Together, our studies demonstrate an essential role of TrkA signaling for stress fracture repair and implicate skeletal sensory nerves as an important upstream mediator of this repair process.
MA20.07 Thymomectomy and Total Thymectomy or Simple Thymomectomy for Early Stage Thymoma Without Myasthenia Gravis: An ESTS Thymic Working Group Study
Authors: F. Guerrera, C. Filippini, L. Voltolini, F. Londero, P. Falcoz, G. Lo Iacono, C. Zisis, P. Mendogni, L. Molins, N. Martucci, G. Rocco, A. Toker, M. Esch, C. Aigner, I. Bravio, S. Mantovani, B. Moser, N. Novoa, B. Verdonck, B. Du Pont, M. Congregado, L. Ampollini, P.A. Thomas, E. Ruffini
Journal: Journal of Thoracic Oncology (2019)
P1.14-09 Unveiling Hidden MET-Mediated Primary Alectinib Resistance in ALK-Positive Non-Small Cell Lung Cancer
Authors: A. Le, L. Tyler, K. Davies, K. Kondo, J. Pacheco, D. Merrick, D. Aisner, D.R. Camidge, R. Doebele
Journal: Journal of Thoracic Oncology (2019)
BuCy Provides Equivalent Outcomes to VCyTBI as Conditioning Prior to Auto-SCT in Patients with Relapsed/Refractory NHL and Is a Valuable Option in Older (≥60 years) Patients.
Authors: Shannon L Smiley, Theresa Hahn, Wei Tan, Gregory Wilding, Minoo Battiwalla, Philip L. McCarthy
Journal: Blood (2008)
P2.14-50 Low Temperature Plasma Needle Induces Cell Cycle Arrest of Epithelial Lung Cancer Cells in Vitro via a p21-Dependent Pathway
Authors: M. Cavic, N. Selakovic, N. Gligorijevic, N. Puac, G. Malovic, S. Radulovic, Z. Petrovic
Journal: Journal of Thoracic Oncology (2019)
P1.03-43 Preoperative Prognostic Value of Immune-Inflammation Index in Patients with Operable Non-Small Cell Lung Cancer
Authors: C. Fraile Olivero, L. Milla Collado, M. Mecho Carratala, A. Ojanguren Arranz, J. Trujillano Cabello, C. Cerdan Santacruz, M. Montesinos, C. Rombolá
Journal: Journal of Thoracic Oncology (2019)
EP1.01-105 Experience in Treating Recurrent Non-Small Lung Cancer Patients After Surgery with Immune-Checkpoint Inhibitor
Authors: M. Yamaguchi, T. Matsubara, S. Takamori, N. Haratake, R. Toyozawa, N. Miura, T. Seto, M. Takenoyama
Journal: Journal of Thoracic Oncology (2019)
P2.01-21 Efficacy and Safety of Combing Anlotinib and Erlotinib as a First-Line Therapy in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
Authors: B. Han, T. Chu, C. Shi, H. Zhong, W. Zhang, B. Zhang, R. Zhong, X. Zhang
Journal: Journal of Thoracic Oncology (2019)
OA12.05 Imaging-Guided Target Volume Reduction in Radiotherapy of Lung Cancer: The Prospective Randomized Multinational PET-Plan Trial
Authors: U. Nestle, T. Schimek-Jasch, S. Kremp, A. Schaefer, A. Kuesters, M. Tosch, T. Hehr, M. Eschmann, Y. Bultel, P. Hass, J. Fleckenstein, A. Thieme, M. Stockinger, M. Miederer, G. Holl, C. Rischke, S. Adebahr, E. Gkika, J. Koenig, A. Grosu
Journal: Journal of Thoracic Oncology (2019)
EP1.03-18 Analysis of IDH1 Mutation Spectrum from Non-Small-Cell Lung Cancer in East Asian Patients
Authors: L. Wang, C. Xu, W. Wang, Q. Zhang, W. Zhuang, Y. Zhu, Z. Huang, G. Chen, M. Fang, T. Lv, Y. Song
Journal: Journal of Thoracic Oncology (2019)
Is plasma renin activity associated with worse outcomes in acute heart failure? A secondary analysis from the BLAST‐AHF trial
Authors: Rayan Jo Rachwan, Javed Butler, Sean P. Collins, Gad Cotter, Beth A. Davison, Stefanie Senger, Justin A. Ezekowitz, Gerasimos Filippatos, Phillip D. Levy, Marco Metra, Piotr Ponikowski, John R. Teerlink, Adriaan A. Voors, Rudolf A. de Boer, David G. Soergel, G. Michael Felker, Peter S. Pang
Journal: European Journal of Heart Failure (2019)